Concise Communication

Antimicrobial activity of a continuously active disinfectant against healthcare pathogens

William A. Rutala PhD, MPH1, Maria F. Gergen MT (ASCP)2, Emily E. Sickbert-Bennett PhD1,3, Deverick J. Anderson MD, MPH4 and David J. Weber MD, MPH1,3, for the CDC Prevention Epicenters Program

1Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, North Carolina, 2Lumagenics, Cary, North Carolina, 3Department of Hospital Epidemiology, University of North Carolina Health Care, Chapel Hill, North Carolina and 4Division of Infectious Diseases, Duke Center for Antimicrobial Stewardship and Infection Prevention, Duke University Medical Center, Durham, North Carolina

Abstract

A novel disinfectant studied using an EPA protocol demonstrated sustained antimicrobial activity (ie, 3–5 log10 reduction) in 5 minutes after 24 hours for Staphylococcus aureus, vancomycin-resistant Enterococcus, Candida auris, carbapenem-resistant Escherichia coli and antibiotic-susceptible E. coli, and Enterobacter spp. Only ~2 log10 reduction occurred with carbapenem-resistant Enterobacter spp and K. pneumoniae, and antibiotic-susceptible K. pneumoniae.

(Received 14 May 2019; accepted 24 August 2019)

Environmental contamination plays an important role in the transmission of several key healthcare-associated pathogens, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Clostridioides difficile, and Acinetobacter. Ample evidence supporting the role of the contaminated surface environment in the transmission of healthcare pathogens has been published: surfaces are frequently contaminated; pathogens survive for days (eg, vegetative bacteria) to months (ie, C. difficile spores); contact with surfaces results in hand and/or glove contamination; disinfection reduces surface and hand contamination via touch and healthcare-associated infections; rooms are inadequately cleaned and disinfected; patients admitted to a room previously occupied by a patient colonized or infected with a pathogen (eg, MRSA, VRE, or C. difficile) have an increased likelihood of developing colonization or infection with that pathogen, which can be reduced by improved terminal disinfection (eg, ultraviolet irradiation [UV]). However, a limitation of “no touch” technologies, such as UV, is that they can only be used for terminal room disinfection because they require removal of all persons from the room. In addition, microbial contamination of environmental surfaces and noncritical patient-care items occurs continuously via patients, visitors, and staff. The intent of routine (eg, daily) disinfection is to make surfaces and equipment hygienically clean (not sterile), that is, free of pathogens in sufficient numbers to prevent human disease. If an antimicrobial residue remains on a disinfected surface and it persists on the surface for 24 hours, it could guard against recontamination with healthcare pathogens for 24 hours. In this study, we evaluated a novel disinfectant that is registered by the Environmental Protection Agency (EPA) to kill microbes on surfaces for at least 24 hours.

Methods

We investigated the continuously active disinfectant (CAD) against healthcare pathogens using an EPA "Protocol for Residual Self-Sanitizing Activity of Dried Chemical Residuals on Hard, Non-Porous Surfaces." The method simulates contact and touches by incorporating “wear” of the test surface as well as reinculations of the test and control surfaces over 24 hours. The test surfaces were inoculated with 104 test organisms (9 test microbes, see Table 1), treated with the novel disinfectant, allowed to dry, and then abraded using a standardized abrasion machine under multiple alternating wet and dry wiping conditions (6 dry cycles, 6 wet cycles, total 12 cycles [2 passes per cycle = 24 passes]) interspersed with 6 reinculations with 103 colony-forming units (CFU) of the test pathogen. The protocol requires a Gardco Washability and Wear tester (Gardner, Pompano Beach, FL) to perform the repeat abrasion portion of the test. After 24 hours, the surface was reinculated (106 CFU) a final time, and the ability of the disinfectant to kill >99.9% of the 9 test microbes within 5 minutes was measured on 3 test surfaces: glass, formica, and stainless steel. The neutralizer used in the test was 1.5% lecithin and 5% Tween 80 (w/v) in sterile distilled water.

The novel disinfectant is EPA registered as Firebird F130 (Microban Products, Huntersville, NC) and marketed by Professional Disposables International (Woodcliff Lake, NJ). It has a 24-hour residual disinfectant claim and contains (w/w): 0.276% alkyl dimethyl benzyl ammonium chloride (50%C14, 40%C12, 10%C16); 0.104% didecyl dimethyl ammonium chloride; 0.207% octyl decyl dimethyl ammonium chloride; 0.104% dioctyl...
dimethyl ammonium chloride; 68.61% ethanol, as well as proprietary agents designed to increase longevity on the surface.⁵

Results

The novel disinfectant demonstrated a 3–5 log₁₀ reduction in 5 minutes when testing *S. aureus*, VRE, *C. auris*, carbapenem-resistant *E. coli* and antibiotic-sensitive strains of *E. coli*, and *Enterobacter* spp (Table 1). The disinfectant demonstrated lower reductions of carbapenem-resistant isolates of *Enterobacter* spp and *K. pneumoniae*, and of antibiotic-sensitive *K. pneumoniae* (~2 log₁₀ reduction in 5 minutes). When the novel disinfectant was compared to 3 other commonly used disinfectants using the same methodology with *S. aureus*, the mean log₁₀ reductions were as follows: 4.4 for novel disinfectant; 0.9 for quaternary ammonium compound with alcohol; 0.2 for improved hydrogen peroxide; and 0.1 for chlorine.

Discussion

After cleaning and disinfection, surfaces can rapidly become recontaminated.⁶ Thus, hands or gloves of healthcare providers can become colonized or contaminated by touching contaminated environmental surfaces and patient-care equipment. Then, via inadequate hand hygiene or inappropriate glove use, healthcare providers can transfer pathogens to patients. Because routine cleaning of room surfaces by environmental services staff is frequently inadequate,² continuous room decontamination methods would fulfill an unmet need for cleaning and disinfection. The intent of this technology is to make surfaces hygienically clean (not sterile), that is, free of pathogens in sufficient numbers to prevent human disease. Technologies that could achieve and maintain low levels of microbial contamination include visible light disinfection (eg, high-intensity narrow-spectrum light), low concentration hydrogen peroxide, CAD, and self-disinfection surfaces (eg, copper).³ These technologies highlight the potential to interrupt transmission from contaminated surfaces and equipment⁷ by pathogen elimination from surfaces via healthcare provider hands and suboptimal compliance with hand hygiene or inappropriate glove use. These technologies are under active investigation to evaluate clinical efficacy, but to date, only copper has been assessed for the ability to reduce HAIs.

Our findings, which demonstrate the 3–5 log₁₀ reductions of epidemiologically important pathogens in 5 minutes over 24 hours using a new CAD, are promising. The reason for a ~2-log₁₀ reduction (99% reduction) with carbapenem-resistant *Enterobacter* and *Klebsiella* and sensitive *Klebsiella pneumoniae* in our study is unclear. Another investigator found a 4 log₁₀ reduction for these pathogens (personal communication, C Donskey), and most surfaces have <100 CFU/Rodac (25 cm²) in the clinical environment.³ Importantly, the novel disinfectant achieved significant sustained antimicrobial activity in 5 minutes against most pathogens after 24 hours of “wear” and reinoculations. The results of this comparative evaluation demonstrate both no residual efficacy for the chlorine or improved hydrogen peroxide and nonsubstantial residual antimicrobial efficacy for the quaternary ammonium compound.

If the microbial load on surfaces is pathogen free or if pathogens are substantially reduced, the treated surface will not act as a reservoir for pathogens and, thus, will not be linked to disease transmission. Thus, CAD⁸,⁹ (and other continuous room decontamination technologies) may reduce or eliminate the problem of recontamination and minimize the role of contaminated environmental surfaces and equipment in transmission of healthcare pathogens.

These data are preliminary, and further studies are needed to determine whether the use of this disinfectant in a clinical environment reduces both microbial contamination and, ultimately, healthcare-associated infections. This study also has several potential limitations. Only 3 surfaces (ie, glass, formica, and stainless steel) were tested, and some surfaces (eg, bed rails) may undergo more touches than the number used for testing in this study. A pilot study with this CAD demonstrated superior reduction of microbial load over 24 hours compared to a dilutable quaternary ammonium compound or a disinfectant with ethanol and a quaternary ammonium compound with alcohol; 0.2 for improved hydrogen peroxide; and 0.1 for chlorine.

Table 1. Log₁₀ Reduction of a Novel Disinfectant with Persistent Antimicrobial Activity

| Site | Test Pathogen | Mean Log₁₀ Reduction (95% CI) (n=4) |
|------|---------------|-------------------------------------|
| A    | *Staphylococcus aureus* |
| B    | *S. aureus* (formica) |
| C    | *S. aureus* (stainless steel) |
| D    | Vancomycin-resistant *Enterococcus* |
| E    | *Escherichia coli* |
| F    | *Enterobacter* spp |
| G    | *Candida auris* |
| H    | *Klebsiella pneumoniae* |
| I    | CRE *E. coli* |
| J    | CRE *Enterobacter* |
| K    | CRE *K. pneumoniae* |

Note. CI, confidence interval; CRE, carbapenem-resistant *Enterobacteriaceae*. *Test surface was glass.*

Acknowledgements. The Gardco tester (Gardner, Pompano Beach, FL) was loaned to UNC Hospitals by Professional Disposables International. The novel disinfectant (Firebird FL30) was provided by Microban Products (Huntersville, NC).

Financial support. This study was supported by UNC Health Care and the Centers for Disease Control and Prevention’s Prevention Epicenters Program (grant no. U54CK000483.)
Conflict of interest. Drs Rutala and Weber are consultants for Professional Disposable International. All other authors report no conflict of interest relevant to this article.

References

1. Weber DJ, Anderson D, Rutala WA. The role of the surface environment in healthcare-associated infections. *Curr Opin Infect Dis* 2013;26:338–344.
2. Rutala WA, Weber DJ. Best practices for disinfection of noncritical environmental surfaces and equipment in health care facilities: a bundle approach. *Am J Infect Control* 2019;47S:A96–A105.
3. Huslage K, Rutala WA, Sickbert-Bennett E, Weber DJ. A quantitative approach to defining “high-touch” surfaces in hospitals. *Infect Control Hosp Epidemiol* 2010;31:850–853.
4. Protocol for residual self-sanitizing activity of dried chemical residuals on hard, non-porous surfaces. Environmental Protection Agency website. https://www.epa.gov/sites/production/files/2015-09/documents/cloroxpcol_final.pdf. Published 2015. Accessed September 3, 2019.
5. Schmidt MG, Fairey SE, Attaway HH. In situ evaluation of a persistent disinfectant provides continuous decontamination within the clinical environment. *Am J Infect Control* 2019;47:732–734.
6. Hardy KJ, Gossain S, Henderson N, et al. Rapid recontamination with MRSA of the environment of an intensive care unit after decontamination with hydrogen peroxide vapour. *J Hosp Infect* 2007;66:360–368.
7. Suwantarat N, Supple LA, Cadnum JL, Sankar T, Donskey CJ. Quantitative assessment of interactions between hospitalized patients and portable medical equipment and other fomites. *Am J Infect Control* 2017;45:1276–1278.
8. Tamimi AH, Carlino S, Gerba CP. Long-term efficacy of a self-disinfecting coating in an intensive care unit. *Am J Infect Control* 2014;42:1178–1181.
9. Rutala WA, Weber DJ. New disinfection and sterilization methods. *Emerg Infect Dis* 2001;7:348–353.
10. Weber DJ, Rutala WA. 2006. Use of germicides in the home and health care setting: Is there a relationship between germicide use and antimicrobial resistance? *Infect Control Hosp Epidemiol* 27:1107–1119.